| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | STMN2 |
| Uniprot No | Q93045 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-179aa |
| 氨基酸序列 | MAKTAMAYKEKMKELSMLSLICSCFYPEPRNINIYTYDDMEVKQINKRASGQAFELILKPPSPISEAPRTLASPKKKDLSLEEIQKKLEAAEERRKSQEAQVLKQLAEKREHEREVLQKALEENNNFSKMAEEKLILKMEQIKENREANLAAIIERLQEKERHAAEVRRNKELQVELSG |
| 预测分子量 | 27.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于STMN2重组蛋白的模拟参考文献示例(基于公开研究方向的合理推测，非真实文献)：
---
1. **文献名称**：*Recombinant human STMN2 promotes axonal regeneration in a neuronal injury model*
**作者**：Zhang L, et al.
**摘要**：研究通过大肠杆菌系统表达并纯化重组STMN2蛋白，发现其在体外实验中显著促进神经元轴突再生，提示其可能通过调节微管动力学参与神经修复。
2. **文献名称**：*STMN2 loss in ALS disrupts microtubule stability and is rescued by recombinant protein delivery*
**作者**：Klim JR, et al.
**摘要**：该文献发现肌萎缩侧索硬化症(ALS)患者中STMN2表达缺失导致微管不稳定，并通过重组STMN2蛋白递送恢复神经元微管结构，为治疗提供潜在策略。
3. **文献名称**：*Crystal structure of recombinant STMN2 reveals tubulin-binding domain interactions*
**作者**：Wang Y, et al.
**摘要**：利用重组STMN2蛋白解析其晶体结构，揭示其与微管蛋白结合的分子机制，为设计靶向微管的药物提供结构基础。
4. **文献名称**：*Recombinant STMN2 as a serum biomarker for early-stage neurodegenerative disorders*
**作者**：Fernandez M, et al.
**摘要**：开发基于重组STMN2蛋白的检测方法，发现其在阿尔茨海默病患者血清中水平异常，提示其作为神经退行性疾病生物标志物的潜力。
---
**说明**：以上文献为示例性内容，实际研究中请通过学术数据库(如PubMed、Web of Science)检索真实文献。STMN2(Stathmin-2)的研究多聚焦于神经退行性疾病机制、微管调控及重组蛋白治疗应用方向。
**Background of STMN2 Recombinant Protein**
STMN2 (Stathmin-2), also known as SCG10. is a neuronal microtubule-regulating protein encoded by the *STMN2* gene. It belongs to the stathmin family, which modulates microtubule dynamics by binding to tubulin and promoting depolymerization or preventing polymerization. STMN2 is predominantly expressed in the nervous system, where it plays a critical role in axonal outgrowth, synaptic plasticity, and intracellular transport. Its activity is tightly regulated by phosphorylation, which influences its ability to interact with microtubules. Dysregulation of STMN2 has been implicated in neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and traumatic nerve injury.
Recombinant STMN2 protein is engineered *in vitro* using expression systems like *E. coli* or mammalian cells, ensuring high purity and bioactivity for research applications. It serves as a vital tool for studying microtubule dynamics, neuronal development, and repair mechanisms. Recent studies highlight its potential as a biomarker in ALS, where reduced STMN2 levels correlate with disease progression. Additionally, STMN2’s role in axonal regeneration has spurred interest in therapeutic strategies targeting its expression or activity to treat neurodegenerative conditions.
Research on STMN2 also explores its interaction with other proteins, such as tau, which is linked to Alzheimer’s pathology. By providing a controlled source of the protein, recombinant STMN2 facilitates drug screening, structural studies, and mechanistic investigations, advancing our understanding of neuronal health and disease. Its dual role as a disease modifier and regeneration promoter underscores its significance in both basic neuroscience and translational medicine.
×
